Dr. Victor Lewis, MD
Claim this profileAlberta Children's Hospital
Studies Leukemia
Studies Lymphoblastic Leukemia-Lymphoma
27 reported clinical trials
77 drugs studied
About Victor Lewis, MD
Education:
- Completed medical training in Pakistan.
Experience:
- Served as an internist before specializing further.
- Retrained in Pediatrics, Pediatric Hematology/Oncology, and Transplantation at the University of Minnesota, USA.
- Has been with the University of Calgary and Alberta Children's Hospital since 2002, focusing on pediatric leukemia, lymphoma, and transplantation.
- Currently the Director of the Oncology and Blood and Marrow Transplant sections at Alberta Children's Hospital.
- Co-leads both the Phase I/II program and the developmental therapeutics program at the institution.
Area of expertise
1Leukemia
BCR-ABL1 fusion positive
ABL-class fusion positive
Philadelphia chromosome positive
2Lymphoblastic Leukemia-Lymphoma
BCR-ABL1 fusion positive
ABL-class fusion positive
CD19 positive
Affiliated Hospitals
Clinical Trials Victor Lewis, MD is currently running
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting2 awards Phase 3
Tabelecleucel
for Post-Transplant Cancer
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of (1) solid organ transplant (SOT) after failure of rituximab and rituximab plus chemotherapy or (2) allogeneic hematopoietic cell transplant (HCT) after failure of rituximab.
Recruiting2 awards Phase 312 criteria
More about Victor Lewis, MD
Clinical Trial Related4 years of experience running clinical trials · Led 27 trials as a Principal Investigator · 14 Active Clinical TrialsTreatments Victor Lewis, MD has experience with
- Cyclophosphamide
- Etoposide
- Radiation Therapy
- Vincristine Sulfate
- Carboplatin
- Dexamethasone
Breakdown of trials Victor Lewis, MD has run
Leukemia
Lymphoblastic Leukemia-Lymphoma
Acute Lymphoblastic Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Victor Lewis, MD specialize in?
Victor Lewis, MD focuses on Leukemia and Lymphoblastic Leukemia-Lymphoma. In particular, much of their work with Leukemia has involved BCR-ABL1 fusion positive patients, or patients who are ABL-class fusion positive.
Is Victor Lewis, MD currently recruiting for clinical trials?
Yes, Victor Lewis, MD is currently recruiting for 13 clinical trials in Calgary Alberta. If you're interested in participating, you should apply.
Are there any treatments that Victor Lewis, MD has studied deeply?
Yes, Victor Lewis, MD has studied treatments such as Cyclophosphamide, Etoposide, Radiation Therapy.
What is the best way to schedule an appointment with Victor Lewis, MD?
Apply for one of the trials that Victor Lewis, MD is conducting.
What is the office address of Victor Lewis, MD?
The office of Victor Lewis, MD is located at: Alberta Children's Hospital, Calgary, Alberta T3A 6A8 Canada. This is the address for their practice at the Alberta Children's Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.